{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:51:14Z","timestamp":1762458674088},"reference-count":4,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.eururo.2009.02.025","type":"journal-article","created":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T09:19:29Z","timestamp":1235899169000},"page":"392-394","source":"Crossref","is-referenced-by-count":7,"title":["Reduction of Serum Prostate-Specific Antigen Levels following Varicella-Zoster Infection and Valaciclovir Treatment in Prostate Cancer"],"prefix":"10.1016","volume":"56","author":[{"given":"Roy R.","family":"Jurhill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitze","family":"van der Veen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert J.L.H.","family":"van Leenders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.M.S.","family":"Verhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2009.02.025_bib1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ejca.2006.02.011","article-title":"Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials","volume":"42","author":"Collette","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2009.02.025_bib2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1373\/clinchem.2004.046086","article-title":"Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice","volume":"51","author":"S\u00f6l\u00e9tormos","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.eururo.2009.02.025_bib3","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1089\/104303401753204535","article-title":"Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy","volume":"12","author":"Miles","year":"2001","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.eururo.2009.02.025_bib4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.mt.6300068","article-title":"Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer","volume":"15","author":"Freytag","year":"2008","journal-title":"Mol Ther"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809001997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809001997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T09:25:52Z","timestamp":1545384352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283809001997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":4,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0302283809001997"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2009.02.025","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}